BetterScholar BetterScholar

G. Siber

Vaccine, Clinical Infectious Diseases, The Pediatric Infectious Disease Journal, Journal of the American Medical Association, The Lancet, Pharmaceutical biotechnology, New England Journal of Medicine Show more
12
Role
Title
Level Year L/R
🐜 Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
17 auth. S. Black, H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. Hansen, L. Elvin, K. Ensor, J. Hackell, G. Siber, ... F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, K. Edwards 		11 2000
11
🐜
🐢 Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.
William P. Hausdorff, J. Bryant, P. Paradiso, G. Siber 		9 2000
9
🐢
🐜 Evidence for antibody as a protective correlate for COVID-19 vaccines
8 auth. Kristen A. Earle, D. Ambrosino, Andrew J Fiore-Gartland, D. Goldblatt, P. Gilbert, G. Siber, ... P. Dull, Stanley A Plotkin 		9 2021
9
🐜
🐜 Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial.
10 auth. S. Meydani, M. Meydani, J. Blumberg, L. Leka, G. Siber, R. Loszewski, ... C. Thompson, Marcos C. Pedrosa, R. Diamond, B. Stollar 		9 1997
9
🐜
🐢 Adjuvants for human vaccines--current status, problems and future prospects.
Rajesh Gupta, G. Siber 		9 1995
9
🐢
🐜 Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial
14 auth. K. O'Brien, L. Moulton, R. Reid, R. Weatherholtz, J. Oski, L. Brown, G. Kumar, A. Parkinson, D. Hu, J. Hackell, ... I. Chang, R. Kohberger, G. Siber, M. Santosham 		8 2003
8
🐜
🐜 Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.
12 auth. L. Jodar, J. Butler, G. Carlone, R. Dagan, D. Goldblatt, H. Käyhty, ... K. Klugman, B. Plikaytis, G. Siber, R. Kohberger, I. Chang, T. Cherian 		8 2003
8
🐜
🐢 The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.
William P. Hausdorff, J. Bryant, C. Kloek, P. Paradiso, G. Siber 		8 2000
8
🐢
🐢 Adjuvant properties of aluminum and calcium compounds.
Rajesh Gupta, Bradford Rost, E. Relyveld, G. Siber 		8 1995
8
🐢
🦁 Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
10 auth. G. Siber, I. Chang, S. Baker, P. Fernsten, K. O'Brien, M. Santosham, ... K. Klugman, S. Madhi, P. Paradiso, R. Kohberger 		8 2007
8
🦁
🐬 Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency.
D. Umetsu, D. Ambrosino, I. Quinti, G. Siber, R. Geha 		8 1985
8
🐬
🐬 Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.
M. J. Alonso, Rajesh Gupta, Caroline Min, G. Siber, R. Langer 		8 1994
8
🐬